Business · Companies · 5 hrs ago
Fresenius to sell FMC shares for about €523 million
Fresenius plans to sell 13.4 million shares in Fresenius Medical Care, its former dialysis subsidiary.
The Bad Homburg-based healthcare group announced on Wednesday that it would place the shares with institutional investors overnight.
The sale would cut Fresenius’s stake from 25% to about 20%.
The banks managing the sale indicated a price of €39 per share, and the placement was several times oversubscribed at that level.
Fresenius expects to raise nearly €523 million, after selling €300 million of FMC shares in August.
The company says it will use the proceeds to invest in growth areas; Fresenius has treated FMC as a financial investment for some time.
Fresenius plans to sell 13.4 million shares in Fresenius Medical Care (FMC) for about €523 million.
The sale would reduce Fresenius’s stake in FMC from 25% to around 20%.
The shares are being placed with institutional investors.
Banks indicated a price of €39 per share, a 4.4% discount to Wednesday’s Xetra closing price.
Fresenius says the proceeds will give it more room to invest in growth areas.
- Who
- Fresenius is selling shares in Fresenius Medical Care (FMC) to institutional investors.
- What
- It plans to place 13.4 million FMC shares for about €523 million.
- When
- Fresenius announced the placement on Wednesday evening; the article was published on 11 November 2026.
- Where
- The placement is with institutional investors; the location is not stated.
- Why
- Fresenius says the sale will create room to invest capital in its growth platforms.
This story does not have two clearly opposing sides.
Fresenius sold FMC shares worth €300 million, reducing its stake from just under 28% to 25%.
Fresenius announced it would place 13.4 million FMC shares with institutional investors.
- Shares to be placed
- 13.4 million FMC shares
- Expected proceeds
- About €523 million
- Indicative price
- €39 per share
- Discount
- 4.4% to Wednesday’s Xetra closing price
- Stake after sale
- Around 20% of FMC
What people are saying
Mit der strukturierten Reduzierung unserer Beteiligung an Fresenius Medical Care schaffen wir zusätzlichen Spielraum, um dieses Kapital gezielt in unsere Wachstumsplattformen zu investieren